Having trouble accessing articles? Reset your cache.

T Cell Sciences, Novartis Pharma AG deal

Novartis obtained options to license TCEL's TP10 soluble complement receptor 1 (SCR-1)

Read the full 121 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE